Photodynamic therapy using talaporfin sodium in the multidisciplinary therapy for cholangiocarcinoma -safety and efficacy-

Photodynamic therapy using talaporfin sodium in the multidisciplinary therapy for cholangiocarcinoma -safety and efficacy- - The safety and efficacy of photodynamic therapy using talaporfin sodium for cholangiocarcinoma

Status

Recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000021378

Enrollment

Registered

2016-03-07

Start date

2014-06-17

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Cholangiocarcinoma

Interventions

The photosensitizer talaporfin sodium is injected intravenously at a dose of 40 mg/m2) 6 hours before PDT. Photoactivation with the diode laser system is performed at 664 nm with a light dose of 100

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: -Cholangiocarcinima -No metastasis -Total bilirubin <5mg/dL -Performance status of 0, 1 or 2

Exclusion criteria

Exclusion criteria: -Hypersensitivity for talaporfin sodium -Uncontrollable infection -Severe psychiatric disorder -Severe comorbidity -Pregnancy

Design outcomes

Primary

Measure	Time frame
Progression free survival	—

Countries

Japan

Contacts

Public ContactItaru Naitoh

Nagoya City University Graduate School of Medical Sciences Department of Gastroenterology and Metabolism

inaito@med.nagoya-cu.ac.jp+81-52-853-8211

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026